Back to results
US 2021/0230250 A1Published application
Novel ctla4-ig immunoadhesins
AssigneeXencor, Inc.
InventorsGregory A. Lazar, Matthew J. Bernett
Life of this patent
Estimating the term…
Abstract
The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
Claims7
-8. (canceled)
An immunoadhesin comprising a first domain comprising a variant CTLA4 and a second domain comprising an IgG Fc region, wherein the variant CTLA4 comprises SEQ ID NO:
- 31.
Dependencies are inferred from the claim text.